Scarica l'app Stockscreener
1.28
1.59%
0.02
Dopo l'orario di chiusura:
1.21
-0.07
-5.47%
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable
CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan
CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - Barchart.com
CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull
CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan
CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com Australia
CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Yahoo Finance
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360
Press Release Distribution & PR Platform - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CNS Pharmaceuticals Inc. (CNSP) reports earnings - qz.com
CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance
Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st
CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - AInvest
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CNSP stock touches 52-week low at $1.49 amid sharp annual decline - Investing.com
CNS Pharmaceuticals shares tumble after clinical trial results By Investing.com - Investing.com South Africa
CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com India
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance
CNS Pharmaceuticals expands stock sale agreement to $43.5 million - Investing.com
CNS Pharmaceuticals expands stock sale agreement to $43.5 million By Investing.com - Investing.com UK
The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting - Yahoo Finance
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Central Nervous System (CNS) Therapeutics Market to Reach USD - openPR
CNS Treatment and Therapy Market Size, Trends & Growth 2025-2035 - Future Market Insights
Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace
Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - Stock Titan
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):